 Jonathan Roach
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 12 | 2026 | 763 | 1.950 |
Why?
| | Biliary Atresia | 6 | 2022 | 144 | 1.800 |
Why?
| | Hepatoblastoma | 9 | 2026 | 52 | 1.710 |
Why?
| | Medical Errors | 2 | 2025 | 119 | 1.360 |
Why?
| | Surgical Oncology | 8 | 2026 | 29 | 1.250 |
Why?
| | Specialties, Surgical | 2 | 2022 | 78 | 1.220 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2026 | 188 | 1.060 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 2025 | 64 | 1.020 |
Why?
| | Adrenocortical Carcinoma | 2 | 2025 | 67 | 1.010 |
Why?
| | Hepatectomy | 2 | 2026 | 268 | 1.000 |
Why?
| | Kidney Neoplasms | 7 | 2026 | 405 | 0.960 |
Why?
| | Liver Transplantation | 6 | 2024 | 779 | 0.930 |
Why?
| | Laparoscopy | 4 | 2026 | 474 | 0.910 |
Why?
| | Carcinoma, Papillary | 1 | 2025 | 78 | 0.890 |
Why?
| | Appointments and Schedules | 1 | 2025 | 98 | 0.850 |
Why?
| | Catheterization, Central Venous | 1 | 2025 | 120 | 0.780 |
Why?
| | Child | 41 | 2026 | 22376 | 0.740 |
Why?
| | Portoenterostomy, Hepatic | 3 | 2022 | 39 | 0.680 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2024 | 365 | 0.630 |
Why?
| | Choledocholithiasis | 3 | 2025 | 19 | 0.620 |
Why?
| | Gallstones | 3 | 2025 | 32 | 0.620 |
Why?
| | Survival Rate | 10 | 2026 | 2003 | 0.620 |
Why?
| | Surgeons | 2 | 2025 | 333 | 0.590 |
Why?
| | Bile Acids and Salts | 1 | 2020 | 162 | 0.590 |
Why?
| | Pediatrics | 3 | 2025 | 1073 | 0.590 |
Why?
| | Child, Preschool | 20 | 2026 | 11599 | 0.550 |
Why?
| | Infant | 20 | 2026 | 9849 | 0.540 |
Why?
| | Cholestasis | 1 | 2020 | 209 | 0.530 |
Why?
| | Neoplasms | 4 | 2025 | 2798 | 0.530 |
Why?
| | Pancreatic Neoplasms | 1 | 2025 | 924 | 0.510 |
Why?
| | Quality Improvement | 2 | 2025 | 1259 | 0.510 |
Why?
| | Wilms Tumor | 3 | 2023 | 84 | 0.490 |
Why?
| | Appendectomy | 3 | 2023 | 88 | 0.480 |
Why?
| | Retrospective Studies | 27 | 2026 | 16647 | 0.470 |
Why?
| | Patient Safety | 1 | 2019 | 336 | 0.460 |
Why?
| | Adrenalectomy | 2 | 2025 | 71 | 0.450 |
Why?
| | Nephrectomy | 4 | 2026 | 156 | 0.450 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 343 | 0.450 |
Why?
| | Accidents | 1 | 2014 | 44 | 0.420 |
Why?
| | MicroRNAs | 1 | 2020 | 692 | 0.410 |
Why?
| | Appendicitis | 2 | 2023 | 146 | 0.410 |
Why?
| | Digestive System Diseases | 1 | 2013 | 26 | 0.400 |
Why?
| | Humans | 54 | 2026 | 142675 | 0.400 |
Why?
| | Tissue and Organ Harvesting | 1 | 2013 | 75 | 0.380 |
Why?
| | Cholecystectomy, Laparoscopic | 2 | 2023 | 53 | 0.380 |
Why?
| | Abdomen | 1 | 2013 | 140 | 0.370 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2025 | 1096 | 0.370 |
Why?
| | Sarcoma | 3 | 2024 | 200 | 0.360 |
Why?
| | Child Abuse | 2 | 2014 | 548 | 0.350 |
Why?
| | Adolescent | 22 | 2026 | 22135 | 0.350 |
Why?
| | Postoperative Complications | 4 | 2026 | 2869 | 0.350 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 595 | 0.340 |
Why?
| | Internship and Residency | 1 | 2022 | 1233 | 0.340 |
Why?
| | Kidney Transplantation | 1 | 2017 | 692 | 0.330 |
Why?
| | Organ Transplantation | 1 | 2013 | 247 | 0.320 |
Why?
| | Tissue Donors | 1 | 2013 | 410 | 0.310 |
Why?
| | Bile Ducts | 2 | 2020 | 64 | 0.300 |
Why?
| | Brain Injuries | 1 | 2014 | 503 | 0.300 |
Why?
| | Blood Substitutes | 1 | 2009 | 28 | 0.290 |
Why?
| | Inflammation | 1 | 2020 | 2883 | 0.290 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 74 | 0.290 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 3 | 2025 | 212 | 0.280 |
Why?
| | Abdominal Abscess | 1 | 2007 | 25 | 0.270 |
Why?
| | Cellulitis | 1 | 2007 | 55 | 0.270 |
Why?
| | Drainage | 1 | 2007 | 182 | 0.250 |
Why?
| | Cytokines | 2 | 2018 | 2086 | 0.250 |
Why?
| | Lung Neoplasms | 3 | 2026 | 2588 | 0.250 |
Why?
| | Hemoglobins | 1 | 2009 | 373 | 0.250 |
Why?
| | Neoplasm Staging | 3 | 2025 | 1412 | 0.240 |
Why?
| | Female | 24 | 2026 | 76889 | 0.240 |
Why?
| | Conversion to Open Surgery | 1 | 2026 | 22 | 0.240 |
Why?
| | Indocyanine Green | 1 | 2026 | 42 | 0.240 |
Why?
| | Metastasectomy | 1 | 2026 | 22 | 0.240 |
Why?
| | Esophageal Atresia | 1 | 2026 | 30 | 0.230 |
Why?
| | Sentinel Lymph Node | 1 | 2026 | 46 | 0.230 |
Why?
| | Tracheoesophageal Fistula | 1 | 2026 | 37 | 0.230 |
Why?
| | Near Miss, Healthcare | 1 | 2025 | 12 | 0.230 |
Why?
| | Operative Time | 1 | 2026 | 176 | 0.230 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 2775 | 0.230 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2026 | 115 | 0.230 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 862 | 0.230 |
Why?
| | Carcinoma, Medullary | 1 | 2025 | 16 | 0.230 |
Why?
| | Intraoperative Care | 1 | 2025 | 63 | 0.220 |
Why?
| | Length of Stay | 3 | 2026 | 1299 | 0.220 |
Why?
| | Male | 23 | 2026 | 71074 | 0.220 |
Why?
| | Rhabdoid Tumor | 1 | 2026 | 104 | 0.220 |
Why?
| | Soft Tissue Neoplasms | 1 | 2026 | 123 | 0.220 |
Why?
| | Trisomy 18 Syndrome | 1 | 2024 | 5 | 0.220 |
Why?
| | Databases, Factual | 3 | 2026 | 1452 | 0.210 |
Why?
| | Pancreatitis | 1 | 2025 | 135 | 0.210 |
Why?
| | Mesenteric Veins | 1 | 2024 | 23 | 0.210 |
Why?
| | Clinical Protocols | 1 | 2026 | 279 | 0.210 |
Why?
| | Pancreaticoduodenectomy | 1 | 2024 | 129 | 0.200 |
Why?
| | Appendiceal Neoplasms | 1 | 2023 | 28 | 0.200 |
Why?
| | Robotic Surgical Procedures | 1 | 2026 | 177 | 0.200 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2023 | 16 | 0.190 |
Why?
| | Sarcoma, Ewing | 1 | 2024 | 101 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2024 | 76 | 0.190 |
Why?
| | Pancreatectomy | 1 | 2025 | 273 | 0.190 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2023 | 31 | 0.190 |
Why?
| | Combined Modality Therapy | 4 | 2026 | 1242 | 0.190 |
Why?
| | United States | 5 | 2025 | 15496 | 0.190 |
Why?
| | Documentation | 1 | 2024 | 194 | 0.190 |
Why?
| | Follow-Up Studies | 7 | 2026 | 5276 | 0.190 |
Why?
| | Infant, Newborn | 6 | 2026 | 6315 | 0.180 |
Why?
| | Registries | 2 | 2025 | 2224 | 0.180 |
Why?
| | Treatment Outcome | 6 | 2026 | 11341 | 0.180 |
Why?
| | Prognosis | 6 | 2026 | 4159 | 0.180 |
Why?
| | Blood Transfusion | 1 | 2025 | 402 | 0.180 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2022 | 21 | 0.180 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2022 | 21 | 0.180 |
Why?
| | Academic Medical Centers | 1 | 2025 | 534 | 0.180 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 111 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2024 | 249 | 0.170 |
Why?
| | CD79 Antigens | 1 | 2020 | 16 | 0.170 |
Why?
| | Thoracic Wall | 1 | 2020 | 20 | 0.160 |
Why?
| | Thoracic Neoplasms | 1 | 2020 | 39 | 0.160 |
Why?
| | Short Bowel Syndrome | 1 | 2020 | 27 | 0.160 |
Why?
| | Cell Line | 2 | 2020 | 2884 | 0.160 |
Why?
| | Age Factors | 2 | 2025 | 3266 | 0.160 |
Why?
| | Young Adult | 6 | 2026 | 13817 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2025 | 1389 | 0.150 |
Why?
| | Hepatocytes | 1 | 2020 | 219 | 0.150 |
Why?
| | Digestive System Surgical Procedures | 1 | 2020 | 103 | 0.150 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 209 | 0.140 |
Why?
| | Skin Neoplasms | 1 | 2026 | 854 | 0.140 |
Why?
| | Scoliosis | 1 | 2020 | 222 | 0.130 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 495 | 0.130 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5952 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2024 | 693 | 0.130 |
Why?
| | Clinical Competence | 1 | 2025 | 1218 | 0.130 |
Why?
| | Critical Pathways | 1 | 2018 | 107 | 0.130 |
Why?
| | Job Satisfaction | 1 | 2019 | 232 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2020 | 742 | 0.120 |
Why?
| | Postoperative Care | 1 | 2018 | 276 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2024 | 1165 | 0.120 |
Why?
| | Perioperative Care | 1 | 2017 | 222 | 0.110 |
Why?
| | Liver | 2 | 2020 | 1838 | 0.110 |
Why?
| | Child Advocacy | 1 | 2014 | 32 | 0.110 |
Why?
| | Choledochal Cyst | 1 | 2013 | 14 | 0.100 |
Why?
| | Disease Models, Animal | 3 | 2020 | 4528 | 0.100 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 61 | 0.100 |
Why?
| | Lymph Node Excision | 2 | 2025 | 168 | 0.100 |
Why?
| | Patient Selection | 1 | 2017 | 688 | 0.100 |
Why?
| | Mice, Knockout | 1 | 2020 | 3110 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1131 | 0.100 |
Why?
| | Bilirubin | 2 | 2023 | 87 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2018 | 885 | 0.090 |
Why?
| | Forecasting | 1 | 2014 | 383 | 0.090 |
Why?
| | Craniocerebral Trauma | 1 | 2014 | 175 | 0.090 |
Why?
| | Preoperative Care | 1 | 2013 | 376 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2612 | 0.080 |
Why?
| | Time Factors | 3 | 2018 | 7008 | 0.080 |
Why?
| | Mice | 3 | 2020 | 18309 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1496 | 0.080 |
Why?
| | Protoporphyrins | 1 | 2009 | 16 | 0.070 |
Why?
| | Enzyme Induction | 1 | 2009 | 87 | 0.070 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2009 | 124 | 0.070 |
Why?
| | Adult | 5 | 2025 | 39754 | 0.070 |
Why?
| | Transcription Factor RelA | 1 | 2009 | 87 | 0.070 |
Why?
| | Gelsolin | 1 | 2007 | 9 | 0.070 |
Why?
| | Aged | 2 | 2025 | 25297 | 0.070 |
Why?
| | Intestinal Perforation | 1 | 2007 | 45 | 0.070 |
Why?
| | Lymph | 1 | 2007 | 31 | 0.070 |
Why?
| | Colorado | 2 | 2014 | 4569 | 0.070 |
Why?
| | Middle Aged | 2 | 2025 | 35224 | 0.060 |
Why?
| | Parenteral Nutrition, Total | 1 | 2026 | 29 | 0.060 |
Why?
| | Animals | 4 | 2020 | 37904 | 0.060 |
Why?
| | Tuberous Sclerosis | 1 | 1986 | 56 | 0.060 |
Why?
| | Thoracoscopy | 1 | 2026 | 59 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2009 | 612 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 828 | 0.060 |
Why?
| | Cholecystectomy | 1 | 2025 | 59 | 0.060 |
Why?
| | Shock, Hemorrhagic | 1 | 2007 | 202 | 0.060 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2024 | 14 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2026 | 326 | 0.050 |
Why?
| | Pylorus | 1 | 2024 | 18 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 40 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2026 | 727 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 85 | 0.050 |
Why?
| | Enteral Nutrition | 1 | 2026 | 213 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2026 | 917 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 321 | 0.050 |
Why?
| | Aspartate Aminotransferases | 1 | 2023 | 83 | 0.050 |
Why?
| | Remission Induction | 1 | 2024 | 304 | 0.050 |
Why?
| | Recurrent Laryngeal Nerve | 1 | 2023 | 3 | 0.050 |
Why?
| | Common Bile Duct | 1 | 2023 | 14 | 0.050 |
Why?
| | Neuroblastoma | 1 | 2024 | 168 | 0.050 |
Why?
| | Lipase | 1 | 2023 | 72 | 0.050 |
Why?
| | Nephrons | 1 | 2022 | 22 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2023 | 147 | 0.050 |
Why?
| | Lymphoma | 1 | 2024 | 229 | 0.050 |
Why?
| | Monitoring, Intraoperative | 1 | 2023 | 65 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2023 | 86 | 0.050 |
Why?
| | Thyroidectomy | 1 | 2023 | 91 | 0.050 |
Why?
| | Methylene Blue | 1 | 2022 | 24 | 0.050 |
Why?
| | Kidney Diseases | 1 | 1986 | 417 | 0.050 |
Why?
| | Patient Readmission | 1 | 2007 | 720 | 0.040 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2022 | 45 | 0.040 |
Why?
| | Prospective Studies | 2 | 2026 | 7845 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 441 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1064 | 0.040 |
Why?
| | Societies, Medical | 1 | 2025 | 862 | 0.040 |
Why?
| | Universities | 1 | 2003 | 450 | 0.040 |
Why?
| | Acute Disease | 1 | 2023 | 994 | 0.040 |
Why?
| | Risk-Taking | 1 | 2003 | 332 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2023 | 496 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 125 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 453 | 0.040 |
Why?
| | Graft Survival | 1 | 2022 | 505 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2024 | 1320 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2003 | 485 | 0.040 |
Why?
| | Students | 1 | 2003 | 662 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2018 | 169 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2007 | 1892 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 343 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2805 | 0.030 |
Why?
| | Spleen | 1 | 2018 | 514 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 850 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 883 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 443 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2018 | 374 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2851 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1262 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 678 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1323 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1833 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1185 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1722 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2013 | 61 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 319 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2022 | 1319 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2088 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2023 | 2171 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 3068 | 0.020 |
Why?
| | Mesentery | 1 | 2007 | 45 | 0.020 |
Why?
| | Rupture, Spontaneous | 1 | 1986 | 14 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 1986 | 30 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2007 | 148 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 369 | 0.010 |
Why?
| | Actins | 1 | 2007 | 427 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2007 | 740 | 0.010 |
Why?
| | Midwestern United States | 1 | 2003 | 42 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2007 | 2509 | 0.010 |
Why?
| | Contraception | 1 | 2003 | 163 | 0.010 |
Why?
| | Sexually Transmitted Diseases | 1 | 2003 | 166 | 0.010 |
Why?
| | Proteomics | 1 | 2007 | 1167 | 0.010 |
Why?
| | Data Collection | 1 | 2003 | 632 | 0.010 |
Why?
| | School Health Services | 1 | 2003 | 226 | 0.010 |
Why?
| | Rats | 1 | 2007 | 5570 | 0.010 |
Why?
|
|
Roach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|